jRCT2031240717进行中（未招募）不适用
A Phase 3, Randomized, Observer-Blind, Active-Controlled Study to Investigate the Immunogenicity of a Booster Dose of S-268024 Compared with NUVAXOVID (COVID-19)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 730
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Prevention Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Participants aged 18 years or older, at the time of sigining the informed consent form.
- •Participants who have passed 90 days or more after completing the primary or booster vaccination with an approved SARS-CoV-2 vaccine (excluding approved SARS-CoV-2 vaccines for JN.1 variant).
- •Participants with no infection history of SARS-CoV-2, or participants with infection history of SARS-CoV-2 who have not been infected since October
- •Male and female.
排除标准
- •Participants who have previously received an approved SARS-CoV-2 vaccines for JN.1 variant.
- •Participants who tested positive for anti-SARS-CoV-2 N-protein antibody at the screening.
- •Participants who tested positive SARS-CoV-2 infection (as determined by SARS-CoV-2 antigen test) at Visit 1 (before administration).
结局指标
主要结局
-
SARS-CoV-2 neutralizing antibody titer on day 29 (JN.1 variant) -GMT -Seroresponse rate
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 study of S-268019 (COVID-19)JPRN-jRCT2031210269agata Tsutae60
进行中（未招募）
2 期
A Phase 2/3 Study of S-268019 (COVID-19)Prevention of COVID-19JPRN-jRCT2031210383agata Tsutae3,100
已完成
1 期
A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With SchizophreniaSchizophreniaNCT04510298Sirtsei Pharmaceuticals, Inc.27
进行中（未招募）
不适用
A Phase 2 Efficacy And Safety Study Of Su011248 In Patients With Non-Small Cell Lung Cancer And Brain MetastasesEUCTR2006-004451-38-ESPfizer, S.L.U.60
进行中（未招募）
不适用
A phase ii study assesing su-011248 in previously untreated patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapyEstudio fase II que evalúa la eficacia y tolerabilidad de SU-011248 en pacientes previamente no tratados con cáncer uroterial no elegibles para quimioterapia basada en platinoPreviously untreated patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapyEUCTR2005-005115-16-ESJoaquim Bellmunt Molins21